Intel Corp. (0R24)
London Exchange · UK · prices in USD · close of 19 Oct 2026
Key indicators
| Last close | USD 92.42 |
|---|---|
| 52-week range | 32.82 – 142.34 |
| Return, 1 month / 3 months | −16.4% / −6.4% |
| Return, 1 year / 3 years | +149.6% / +159.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 33 |
| Volatility (1 year) | 74.3% |
| Worst drawdown (1 year) | -39.8% |
| Average daily value traded | 85.41M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Intel designs and manufactures semiconductor products, including microprocessors for personal computers and data centres, chipsets, and memory and networking components. Its customers are device makers, computer manufacturers, cloud and enterprise operators, and other technology companies that build hardware around its chips. The company is based in Santa Clara, California, in the United States, and its products sit inside a wide range of computing and communications equipment used by businesses and consumers around the world.
Intel Corp. trades under the code 0R24 on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Intel Corp. (0R24) trades on the London Exchange in UK. It last closed at USD 92.42 on 19 October 2026.
Its price-based Market X-Ray is 59 out of 100 (a fair price profile), ranking 1,385 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 149.6% and over the last three months it fell 6.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 8.7% | ||
| From 52-week high | -34.3% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -6.4% | ||
| 6-month return | 41.4% | ||
| 12-month return, skipping the last month | 198.7% | ||
| Stability (higher is calmer) | 22 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 74.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.8% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 85.41M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −12.4% |
|---|---|
| 1 month | −16.4% |
| 3 months | −6.4% |
| 6 months | +41.4% |
| 1 year | +149.6% |
| 3 years | +159.8% |
| 5 years | – |
Signals
| 50-day / 200-day average | 103.27 / 85.00 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.47 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 7 Aug 2024 | USD 0.1250 |
| 3 May 2024 | USD 0.1250 |
| 6 Feb 2024 | USD 0.1250 |
| 6 Nov 2023 | USD 0.1250 |
| 4 Aug 2023 | USD 0.1250 |
| 4 May 2023 | USD 0.1250 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.